{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:15:35Z","timestamp":1791688535607,"version":"4.3.4"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016737","name":"Patrick C. Walsh Prostate Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11302-024-10054-7","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T04:02:29Z","timestamp":1728532949000},"page":"393-411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["P2 purinergic receptor expression and function in tumor-related immune cells"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9781-4080","authenticated-orcid":false,"given":"Vahinipriya","family":"Manoharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwafemi O.","family":"Adegbayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0448-8552","authenticated-orcid":false,"given":"Janielle P.","family":"Maynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"10054_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41392-021-00553-z","volume":"6","author":"Z Huang","year":"2021","unstructured":"Huang Z, Xie N, Illes P, Di Virgilio F, Ulrich H, Semyanov A, Verkhratsky A, Sperlagh B, Yu S-G, Huang C (2021) From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther 6:162","journal-title":"Signal Transduct Target Ther"},{"key":"10054_CR2","doi-asserted-by":"publisher","first-page":"239821281881749","DOI":"10.1177\/2398212818817494","volume":"2","author":"G Burnstock","year":"2018","unstructured":"Burnstock G (2018) Purine and purinergic receptors. Brain Neurosci Adv 2:2398212818817494","journal-title":"Brain Neurosci Adv"},{"key":"10054_CR3","doi-asserted-by":"crossref","unstructured":"Sarikaya E (2019) Functions of purinergic receptors. In Receptors P1 and P2 as targets for drug therapy in humans, IntechOpen: 2019","DOI":"10.5772\/intechopen.88251"},{"key":"10054_CR4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2174\/1389450120666190213095923","volume":"20","author":"NC da Silva Ferreira","year":"2019","unstructured":"da Silva Ferreira NC, Alves LA, Soares-Bezerra RJ (2019) Potential therapeutic applications of P2 receptor antagonists: from bench to clinical trials. Curr Drug Targets 20:919\u2013937","journal-title":"Curr Drug Targets"},{"key":"10054_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11302-022-09875-1","volume":"18","author":"JP Maynard","year":"2022","unstructured":"Maynard JP, Sfanos KS (2022) P2 purinergic receptor dysregulation in urologic disease. Purinergic Signal 18:267\u2013287","journal-title":"Purinergic Signal"},{"key":"10054_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41523-021-00229-5","volume":"7","author":"D Draganov","year":"2021","unstructured":"Draganov D, Han Z, Rana A, Bennett N, Irvine DJ, Lee PP (2021) Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. NPJ Breast Cancer 7:22","journal-title":"NPJ Breast Cancer"},{"key":"10054_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41467-021-20912-2","volume":"12","author":"L Douguet","year":"2021","unstructured":"Douguet L, dit Hreich SJ, Benzaquen J, Seguin L, Juhel T, Dezitter X, Duranton C, Ryffel B, Kanellopoulos J, Delarasse C (2021) A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy. Nat Comm 12:653","journal-title":"Nat Comm"},{"key":"10054_CR8","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3390\/cells9071612","volume":"9","author":"ADR Campos-Contreras","year":"2020","unstructured":"Campos-Contreras ADR, D\u00edaz-Mu\u00f1oz M, V\u00e1zquez-Cuevas FG (2020) Purinergic signaling in the hallmarks of cancer. Cells 9:1612","journal-title":"Cells"},{"key":"10054_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00109-021-02041-x","volume":"99","author":"X Zhu","year":"2021","unstructured":"Zhu X, Li Q, Song W, Peng X, Zhao R (2021) P2X7 receptor: a critical regulator and potential target for breast cancer. J Mol Med 99:349\u2013358","journal-title":"J Mol Med"},{"key":"10054_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3892\/or.2015.3979","volume":"34","author":"J Xia","year":"2015","unstructured":"Xia J, Yu X, Tang L, Li G, He T (2015) P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway. Oncol Rep 34:103\u2013110","journal-title":"Oncol Rep"},{"key":"10054_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/path.5815","volume":"256","author":"JP Maynard","year":"2022","unstructured":"Maynard JP, Lu J, Vidal I, Hicks J, Mummert L, Ali T, Kempski R, Carter AM, Sosa RY, Peiffer LB (2022) P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer. J Pathol 256:149\u2013163","journal-title":"J Pathol"},{"key":"10054_CR12","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1007\/s13577-022-00729-x","volume":"35","author":"C Qiao","year":"2022","unstructured":"Qiao C, Tang Y, Li Q, Zhu X, Peng X, Zhao R (2022) ATP-gated P2X7 receptor as a potential target for prostate cancer. Hum Cell 35:1346\u20131354","journal-title":"Hum Cell"},{"key":"10054_CR13","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1007\/s00432-020-03379-4","volume":"146","author":"Q Li","year":"2020","unstructured":"Li Q, Zhu X, Song W, Peng X, Zhao R (2020) The P2X7 purinergic receptor: a potential therapeutic target for lung cancer. J Cancer Res Clin Oncol 146:2731\u20132741","journal-title":"J Cancer Res Clin Oncol"},{"key":"10054_CR14","doi-asserted-by":"crossref","unstructured":"Placet M, Arguin G, Molle CM, Babeu J-P, Jones C, Carrier JC, Robaye B, Geha S, Boudreau F, Gendron F-P (2018) The G protein-coupled P2Y6 receptor promotes colorectal cancer tumorigenesis by inhibiting apoptosis. Biochimica et Biophysica Acta (BBA)-Mol Basis Dis 1864:1539\u20131551","DOI":"10.1016\/j.bbadis.2018.02.008"},{"key":"10054_CR15","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1158\/1078-0432.CCR-18-2297","volume":"25","author":"L-P Hu","year":"2019","unstructured":"Hu L-P, Zhang X-X, Jiang S-H, Tao L-Y, Li Q, Zhu L-L, Yang M-W, Huo Y-M, Jiang Y-S, Tian G-A (2019) Targeting purinergic receptor P2Y2 prevents the growth of pancreatic ductal adenocarcinoma by inhibiting cancer cell glycolysis. Clin Cancer Res 25:1318\u20131330","journal-title":"Clin Cancer Res"},{"key":"10054_CR16","doi-asserted-by":"publisher","first-page":"41162","DOI":"10.18632\/oncotarget.6240","volume":"6","author":"JP Maynard","year":"2015","unstructured":"Maynard JP, Lee J-S, Sohn BH, Yu X, Lopez-Terrada D, Finegold MJ, Goss JA, Thevananther S (2015) P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients. Oncotarget 6:41162","journal-title":"Oncotarget"},{"key":"10054_CR17","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/cas.12736","volume":"106","author":"Z Liu","year":"2015","unstructured":"Liu Z, Liu Y, Xu L, An H, Chang Y, Yang Y, Zhang W, Xu J (2015) P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma. Cancer Sci 106:1224\u20131231","journal-title":"Cancer Sci"},{"key":"10054_CR18","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.3390\/cancers15082321","volume":"15","author":"S Ledderose","year":"2023","unstructured":"Ledderose S, Rodler S, Eismann L, Ledderose G, Rudelius M, Junger WG, Ledderose C (2023) P2X1 and P2X7 receptor overexpression is a negative predictor of survival in muscle-invasive bladder cancer. Cancers 15:2321","journal-title":"Cancers"},{"key":"10054_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nature13085","volume":"509","author":"M Idzko","year":"2014","unstructured":"Idzko M, Ferrari D, Eltzschig HK (2014) Nucleotide signalling during inflammation. Nature 509:310\u2013317","journal-title":"Nature"},{"key":"10054_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tips.2006.02.004","volume":"27","author":"N White","year":"2006","unstructured":"White N, Burnstock G (2006) P2 receptors and cancer. Trends Pharmacol Sci 27:211\u2013217","journal-title":"Trends Pharmacol Sci"},{"key":"10054_CR21","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00018-019-03213-2","volume":"77","author":"S M\u00fchleder","year":"2020","unstructured":"M\u00fchleder S, Fuchs C, Bas\u00edlio J, Szwarc D, Pill K, Labuda K, Slezak P, Siehs C, Pr\u00f6ll J, Priglinger E (2020) Purinergic P2Y 2 receptors modulate endothelial sprouting. Cell Mol Life Sci 77:885\u2013901","journal-title":"Cell Mol Life Sci"},{"key":"10054_CR22","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.micinf.2012.07.006","volume":"14","author":"A Rayah","year":"2012","unstructured":"Rayah A, Kanellopoulos JM, Di Virgilio F (2012) P2 receptors and immunity. Microbes Infect 14:1254\u20131262","journal-title":"Microbes Infect"},{"key":"10054_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-023-02859-0","volume":"23","author":"Y Cao","year":"2023","unstructured":"Cao Y, Chen E, Wang X, Song J, Zhang H, Chen X (2023) An emerging master inducer and regulator for epithelial-mesenchymal transition and tumor metastasis: extracellular and intracellular ATP and its molecular functions and therapeutic potential. Cancer Cell Int 23:1\u201316","journal-title":"Cancer Cell Int"},{"key":"10054_CR24","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC (2020) The tumor microenvironment. Curr Biol 30:R921\u2013R925","journal-title":"Curr Biol"},{"key":"10054_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41568-018-0037-0","volume":"18","author":"F Di Virgilio","year":"2018","unstructured":"Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E (2018) Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer 18:601\u2013618","journal-title":"Nat Rev Cancer"},{"key":"10054_CR26","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA (2023) The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41:374\u2013403","journal-title":"Cancer Cell"},{"key":"10054_CR27","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.trecan.2022.07.002","volume":"8","author":"D Denk","year":"2022","unstructured":"Denk D, Greten FR (2022) Inflammation: the incubator of the tumor microenvironment. Trends Cancer 8:901","journal-title":"Trends Cancer"},{"issue":"869\u2013883","key":"10054_CR28","first-page":"e865","volume":"32","author":"\u00d6 Canli","year":"2017","unstructured":"Canli \u00d6, Nicolas AM, Gupta J, Finkelmeier F, Goncharova O, Pesic M, Neumann T, Horst D, L\u00f6wer M, Sahin U (2017) Myeloid cell-derived reactive oxygen species induce epithelial mutagenesis. Cancer Cell 32(869\u2013883):e865","journal-title":"Cancer Cell"},{"key":"10054_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11302-013-9357-4","volume":"9","author":"F Jacob","year":"2013","unstructured":"Jacob F, Novo CP, Bachert C, Van Crombruggen K (2013) Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses. Purinergic Signal 9:285\u2013306","journal-title":"Purinergic Signal"},{"key":"10054_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nri.2016.4","volume":"16","author":"C Cekic","year":"2016","unstructured":"Cekic C, Linden J (2016) Purinergic regulation of the immune system. Nat Rev Immunol 16:177\u2013192","journal-title":"Nat Rev Immunol"},{"key":"10054_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nature08296","volume":"461","author":"MR Elliott","year":"2009","unstructured":"Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461:282\u2013286","journal-title":"Nature"},{"key":"10054_CR32","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1038\/onc.2016.104","volume":"35","author":"C Hernandez","year":"2016","unstructured":"Hernandez C, Huebener P, Schwabe RF (2016) Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene 35:5931\u20135941","journal-title":"Oncogene"},{"key":"10054_CR33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s10495-021-01663-3","volume":"26","author":"A Murao","year":"2021","unstructured":"Murao A, Aziz M, Wang H, Brenner M, Wang P (2021) Release mechanisms of major DAMPs. Apoptosis 26:152\u2013162","journal-title":"Apoptosis"},{"key":"10054_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imbio.2010.03.010","volume":"216","author":"C Marques-da-Silva","year":"2011","unstructured":"Marques-da-Silva C, Burnstock G, Ojcius DM, Coutinho-Silva R (2011) Purinergic receptor agonists modulate phagocytosis and clearance of apoptotic cells in macrophages. Immunobiology 216:1\u201311","journal-title":"Immunobiology"},{"key":"10054_CR35","doi-asserted-by":"publisher","first-page":"13309","DOI":"10.1074\/jbc.M209478200","volume":"278","author":"LK Parvathenani","year":"2003","unstructured":"Parvathenani LK, Tertyshnikova S, Greco CR, Roberts SB, Robertson B, Posmantur R (2003) P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer\u2019s disease. J Biol Chem 278:13309\u201313317","journal-title":"J Biol Chem"},{"key":"10054_CR36","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/bph.15379","volume":"178","author":"G Gruenbacher","year":"2021","unstructured":"Gruenbacher G, Gander H, Dobler G, Rahm A, Klaver D, Thurnher M (2021) The human G protein-coupled ATP receptor P2Y11 is a target for anti-inflammatory strategies. Br J Pharmacol 178:1541\u20131555","journal-title":"Br J Pharmacol"},{"key":"10054_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11060-017-2700-9","volume":"137","author":"MA Curet","year":"2018","unstructured":"Curet MA, Watters JJ (2018) P2Y14 receptor activation decreases interleukin-6 production and glioma GL261 cell proliferation in microglial transwell cultures. J Neurooncol 137:23\u201331","journal-title":"J Neurooncol"},{"key":"10054_CR38","doi-asserted-by":"publisher","first-page":"8177","DOI":"10.3390\/ijms21218177","volume":"21","author":"N Pavlovi\u0107","year":"2020","unstructured":"Pavlovi\u0107 N, Kopsida M, Gerwins P, Heindryckx F (2020) Inhibiting P2Y12 in macrophages induces endoplasmic reticulum stress and promotes an anti-tumoral phenotype. Int J Mol Sci 21:8177","journal-title":"Int J Mol Sci"},{"key":"10054_CR39","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41419-019-2010-6","volume":"10","author":"L Kloss","year":"2019","unstructured":"Kloss L, Dollt C, Schledzewski K et al (2019) ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12. Cell Death Dis 10:760","journal-title":"Cell Death Dis"},{"key":"10054_CR40","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.bbrc.2014.03.048","volume":"446","author":"S Chen","year":"2014","unstructured":"Chen S, Feng W, Yang X, Yang W, Ru Y, Liao J, Wang L, Lin Y, Ren Q, Zheng G (2014) Functional expression of P2X family receptors in macrophages is affected by microenvironment in mouse T cell acute lymphoblastic leukemia. Biochem Biophys Res Commun 446:1002\u20131009","journal-title":"Biochem Biophys Res Commun"},{"key":"10054_CR41","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1158\/2326-6066.CIR-20-0123","volume":"8","author":"J Qin","year":"2020","unstructured":"Qin J, Zhang X, Tan B, Zhang S, Yin C, Xue Q, Zhang Z, Ren H, Chen J, Liu M (2020) Blocking P2X7-mediated macrophage polarization overcomes treatment resistance in lung cancer. Cancer Immunol Res 8:1426\u20131439","journal-title":"Cancer Immunol Res"},{"key":"10054_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jneuroim.2004.04.005","volume":"152","author":"L-H Guo","year":"2004","unstructured":"Guo L-H, Trautmann K, Schluesener HJ (2004) Expression of P2X4 receptor in rat C6 glioma by tumor-associated macrophages and activated microglia. J Neuroimmunol 152:67\u201372","journal-title":"J Neuroimmunol"},{"key":"10054_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1474-8673.2007.00389.x","volume":"27","author":"G Nylund","year":"2007","unstructured":"Nylund G, Hultman L, Nordgren S, Delbro D (2007) P2Y2-and P2Y4 purinergic receptors are over-expressed in human colon cancer. Auton Autacoid Pharmacol 27:79\u201384","journal-title":"Auton Autacoid Pharmacol"},{"key":"10054_CR44","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41467-020-20447-y","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Hu L-P, Qin W-T, Yang Q, Chen D-Y, Li Q, Zhou K-X, Huang P-Q, Xu C-J, Li J (2021) Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Nat Commun 12:174","journal-title":"Nat Commun"},{"key":"10054_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/intimm\/dxaa068","volume":"33","author":"S Yamamoto","year":"2021","unstructured":"Yamamoto S, Matsuo K, Sakai S, Mishima I, Hara Y, Oiso N, Kawada A, Yoshie O, Nakayama T (2021) P2X receptor agonist enhances tumor-specific CTL responses through CD70+ DC-mediated Th17 induction. Int Immunol 33:49\u201355","journal-title":"Int Immunol"},{"key":"10054_CR46","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1158\/0008-5472.CAN-19-3807","volume":"80","author":"A Romagnani","year":"2020","unstructured":"Romagnani A, Rottoli E, Mazza EMC et al (2020) P2X7 receptor activity limits accumulation of T cells within tumors. Cancer Res 80:3906\u20133919","journal-title":"Cancer Res"},{"key":"10054_CR47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/bph.15951","volume":"180","author":"A Baroja-Mazo","year":"2023","unstructured":"Baroja-Mazo A, Pe\u00f1\u00edn-Franch A, Lucas-Ruiz F, de Torre-Minguela C, Alarc\u00f3n-Vila C, Hern\u00e1ndez-Caselles T, Pelegr\u00edn P (2023) P2X7 receptor activation impairs antitumour activity of natural killer cells. Br J Pharmacol 180:111\u2013128","journal-title":"Br J Pharmacol"},{"key":"10054_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114405","volume":"187","author":"R Coutinho-Silva","year":"2021","unstructured":"Coutinho-Silva R, Savio LEB (2021) Purinergic signalling in host innate immune defence against intracellular pathogens. Biochem Pharmacol 187:114405","journal-title":"Biochem Pharmacol"},{"key":"10054_CR49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrurol.2017.167","volume":"15","author":"KS Sfanos","year":"2018","unstructured":"Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM (2018) The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol 15:11\u201324","journal-title":"Nat Rev Urol"},{"key":"10054_CR50","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ccell.2021.05.016","volume":"39","author":"MO Li","year":"2021","unstructured":"Li MO, Wolf N, Raulet DH, Akkari L, Pittet MJ, Rodriguez PC, Kaplan RN, Munitz A, Zhang Z, Cheng S (2021) Innate immune cells in the tumor microenvironment. Cancer Cell 39:725\u2013729","journal-title":"Cancer Cell"},{"key":"10054_CR51","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1042\/cs20220531","volume":"137","author":"Z Strizova","year":"2023","unstructured":"Strizova Z, Benesova I, Bartolini R, Novysedlak R, Cecrdlova E, Foley LK, Striz I (2023) M1\/M2 macrophages and their overlaps - myth or reality? Clin Sci (Lond) 137:1067\u20131093. https:\/\/doi.org\/10.1042\/cs20220531","journal-title":"Clin Sci (Lond)"},{"key":"10054_CR52","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fonc.2020.00188","volume":"10","author":"J Zhou","year":"2020","unstructured":"Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X (2020) Tumor-associated macrophages: recent insights and therapies. Front Oncol 10:188","journal-title":"Front Oncol"},{"key":"10054_CR53","first-page":"1","volume":"2012","author":"N-B Hao","year":"2012","unstructured":"Hao N-B, L\u00fc M-H, Fan Y-H, Cao Y-L, Zhang Z-R, Yang S-M (2012) Macrophages in tumor microenvironments and the progression of tumors. J Immunol Res 2012:1","journal-title":"J Immunol Res"},{"key":"10054_CR54","doi-asserted-by":"publisher","unstructured":"Boutilier AJ, Elsawa SF (2021) Macrophage polarization states in the tumor microenvironment. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms22136995","DOI":"10.3390\/ijms22136995"},{"key":"10054_CR55","doi-asserted-by":"publisher","first-page":"9322","DOI":"10.18632\/oncotarget.2427","volume":"5","author":"YN Joo","year":"2014","unstructured":"Joo YN, Jin H, Eun SY, Park SW, Chang KC, Kim HJ (2014) P2Y2R activation by nucleotides released from the highly metastatic breast cancer cell contributes to pre-metastatic niche formation by mediating lysyl oxidase secretion, collagen crosslinking, and monocyte recruitment. Oncotarget 5:9322","journal-title":"Oncotarget"},{"key":"10054_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr3694","volume":"16","author":"H Jin","year":"2014","unstructured":"Jin H, Eun SY, Lee JS, Park SW, Lee JH, Chang KC, Kim HJ (2014) P2Y2receptor activation by nucleotides released from highly metastatic breast cancer cells increases tumor growth and invasion via crosstalk with endothelial cells. Breast Cancer Res 16:1\u201314","journal-title":"Breast Cancer Res"},{"key":"10054_CR57","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s000180050495","volume":"57","author":"N Johansson","year":"2000","unstructured":"Johansson N, Ahonen M, K\u00e4h\u00e4ri V-M (2000) Matrix metalloproteinases in tumor invasion. Cell Mol life Sci CMLS 57:5\u201315","journal-title":"Cell Mol life Sci CMLS"},{"key":"10054_CR58","doi-asserted-by":"publisher","first-page":"6286","DOI":"10.1080\/21655979.2021.1971029","volume":"12","author":"J Wang","year":"2021","unstructured":"Wang J, Shi W, Miao Y, Gan J, Guan Q, Ran J (2021) Evaluation of tumor microenvironmental immune regulation and prognostic in lung adenocarcinoma from the perspective of purinergic receptor P2Y13. Bioengineered 12:6286\u20136304","journal-title":"Bioengineered"},{"key":"10054_CR59","doi-asserted-by":"publisher","first-page":"107734","DOI":"10.1016\/j.intimp.2021.107734","volume":"98","author":"L Yu","year":"2021","unstructured":"Yu L, Cao S, Li J, Han B, Zhong H, Zhong R (2021) Prognostic value and immune infiltration of a novel stromal\/immune score-related P2RY12 in lung adenocarcinoma microenvironment. Int Immunopharmacol 98:107734","journal-title":"Int Immunopharmacol"},{"key":"10054_CR60","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.18632\/aging.202269","volume":"13","author":"T Fan","year":"2021","unstructured":"Fan T, Zhu M, Wang L, Liu Y, Tian H, Zheng Y, Tan F, Sun N, Li C, He J (2021) Immune profile of the tumor microenvironment and the identification of a four-gene signature for lung adenocarcinoma. Aging (Albany NY) 13:2397","journal-title":"Aging (Albany NY)"},{"key":"10054_CR61","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1158\/0008-5472.CAN-14-1259","volume":"75","author":"E Adinolfi","year":"2015","unstructured":"Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani AL, Rotondo A, Sarti AC, Bonora M, Syberg S, Corigliano D (2015) Accelerated tumor progression in mice lacking the ATP receptor P2X7. Can Res 75:635\u2013644","journal-title":"Can Res"},{"key":"10054_CR62","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41375-022-01794-9","volume":"37","author":"M Casey","year":"2023","unstructured":"Casey M, Segawa K, Law SC, Sabdia MB, Nowlan B, Salik B, Lee C, Winterford C, Pearson S, Madore J (2023) Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma. Leukemia 37:379\u2013387","journal-title":"Leukemia"},{"key":"10054_CR63","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1158\/2159-8290.CD-19-0541","volume":"9","author":"X-Y Li","year":"2019","unstructured":"Li X-Y, Moesta AK, Xiao C, Nakamura K, Casey M, Zhang H, Madore J, Lepletier A, Aguilera AR, Sundarrajan A (2019) Targeting CD39 in cancer reveals an extracellular ATP-and inflammasome-driven tumor immunity. Cancer Discov 9:1754\u20131773","journal-title":"Cancer Discov"},{"issue":"357\u2013373","key":"10054_CR64","first-page":"e359","volume":"52","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Fei M, Zhang G, Liang W-C, Lin W, Wu Y, Piskol R, Ridgway J, McNamara E, Huang H (2020) Blockade of the phagocytic receptor MerTK on tumor-associated macrophages enhances P2X7R-dependent STING activation by tumor-derived cGAMP. Immunity 52(357\u2013373):e359","journal-title":"Immunity"},{"key":"10054_CR65","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/jnr.22538","volume":"89","author":"KM Fang","year":"2011","unstructured":"Fang KM, Wang YL, Huang MC, Sun SH, Cheng H, Tzeng SF (2011) Expression of macrophage inflammatory protein-1\u03b1 and monocyte chemoattractant protein-1 in glioma-infiltrating microglia: involvement of ATP and P2X7 receptor. J Neurosci Res 89:199\u2013211","journal-title":"J Neurosci Res"},{"key":"10054_CR66","first-page":"10","volume":"2019","author":"G Gruenbacher","year":"1870","unstructured":"Gruenbacher G, Gander H, Rahm A, Dobler G, Drasche A, Troppmair J, Nussbaumer W, Thurnher M (1870) The human G protein-coupled ATP receptor P2Y11 is associated with IL-10 driven macrophage differentiation. Front Immunol 2019:10","journal-title":"Front Immunol"},{"key":"10054_CR67","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00018-022-04548-z","volume":"79","author":"D Klaver","year":"2022","unstructured":"Klaver D, Gander H, Dobler G, Rahm A, Thurnher M (2022) The P2Y11 receptor of human M2 macrophages activates canonical and IL-1 receptor signaling to translate the extracellular danger signal ATP into anti-inflammatory and pro-angiogenic responses. Cell Mol Life Sci 79:519","journal-title":"Cell Mol Life Sci"},{"key":"10054_CR68","doi-asserted-by":"publisher","first-page":"670746","DOI":"10.3389\/fgene.2021.670746","volume":"12","author":"Q Li","year":"2021","unstructured":"Li Q, Xu L, Li Y, Yang R, Qiao Q, Wang Y, Wang L, Guo Y, Guo C (2021) P2RY14 is a potential biomarker of tumor microenvironment immunomodulation and favorable prognosis in patients with head and neck cancer. Front Genet 12:670746","journal-title":"Front Genet"},{"key":"10054_CR69","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1\u03b2\u2013dependent adaptive immunity against tumors. Nat Med 15:1170\u20131178","journal-title":"Nat Med"},{"key":"10054_CR70","first-page":"3219","volume":"116","author":"N Bles","year":"2010","unstructured":"Bles N, Di Pietrantonio L, Boeynaems J-M, Communi D (2010) ATP confers tumorigenic properties to dendritic cells by inducing amphiregulin secretion. Blood J Am Soc Hematol 116:3219\u20133226","journal-title":"Blood J Am Soc Hematol"},{"key":"10054_CR71","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/s41590-018-0229-5","volume":"19","author":"S Patel","year":"2018","unstructured":"Patel S, Fu S, Mastio J, Dominguez GA, Purohit A, Kossenkov A, Lin C, Alicea-Torres K, Sehgal M, Nefedova Y (2018) Unique pattern of neutrophil migration and function during tumor progression. Nat Immunol 19:1236\u20131247","journal-title":"Nat Immunol"},{"key":"10054_CR72","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.4049\/jimmunol.2000750","volume":"207","author":"Z Li","year":"2021","unstructured":"Li Z, Gao Y, He C, Wei H, Zhang J, Zhang H, Hu L, Jiang W (2021) Purinergic receptor P2Y6 is a negative regulator of NK cell maturation and function. J Immunol 207:1555\u20131565","journal-title":"J Immunol"},{"key":"10054_CR73","doi-asserted-by":"publisher","first-page":"eaba3300","DOI":"10.1126\/scisignal.aba3300","volume":"13","author":"C Ledderose","year":"2020","unstructured":"Ledderose C, Bromberger S, Slubowski CJ, Sueyoshi K, Aytan D, Shen Y, Junger WG (2020) The purinergic receptor P2Y11 choreographs the polarization, mitochondrial metabolism, and migration of T lymphocytes. Sci Signal 13:eaba3300","journal-title":"Sci Signal"},{"key":"10054_CR74","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.4049\/jimmunol.1103800","volume":"189","author":"S Trabanelli","year":"2012","unstructured":"Trabanelli S, O\u010dadl\u00edkov\u00e1 D, Gulinelli S, Curti A, Salvestrini V, de Paula Vieira R, Idzko M, Di Virgilio F, Ferrari D, Lemoli RM (2012) Extracellular ATP exerts opposite effects on activated and regulatory CD4+ T cells via purinergic P2 receptor activation. J Immunol 189:1303\u20131310","journal-title":"J Immunol"},{"key":"10054_CR75","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1038\/s41388-019-0684-y","volume":"38","author":"E De Marchi","year":"2019","unstructured":"De Marchi E, Orioli E, Pegoraro A, Sangaletti S, Portararo P, Curti A, Colombo MP, Di Virgilio F, Adinolfi E (2019) The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene 38:3636\u20133650","journal-title":"Oncogene"},{"key":"10054_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-016-0405-5","volume":"5","author":"C Zhu","year":"2017","unstructured":"Zhu C, Kros JM, van der Weiden M, Zheng P, Cheng C, Mustafa DA (2017) Expression site of P2RY12 in residential microglial cells in astrocytomas correlates with M1 and M2 marker expression and tumor grade. Acta Neuropathol Commun 5:1\u201312","journal-title":"Acta Neuropathol Commun"},{"key":"10054_CR77","doi-asserted-by":"publisher","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","volume":"14","author":"DJ Waugh","year":"2008","unstructured":"Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735\u20136741","journal-title":"Clin Cancer Res"},{"key":"10054_CR78","doi-asserted-by":"publisher","first-page":"5186","DOI":"10.3390\/ijms21155186","volume":"21","author":"S Kadomoto","year":"2020","unstructured":"Kadomoto S, Izumi K, Mizokami A (2020) The CCL20-CCR6 axis in cancer progression. Int J Mol Sci 21:5186","journal-title":"Int J Mol Sci"},{"key":"10054_CR79","doi-asserted-by":"publisher","first-page":"e0120855","DOI":"10.1371\/journal.pone.0120855","volume":"10","author":"Q Yu","year":"2015","unstructured":"Yu Q, Lou X-M, He Y (2015) Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway. PLoS ONE 10:e0120855","journal-title":"PLoS ONE"},{"key":"10054_CR80","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajpath.2012.08.041","volume":"182","author":"J Ye","year":"2013","unstructured":"Ye J, Livergood RS, Peng G (2013) The role and regulation of human Th17 cells in tumor immunity. Am J Pathol 182:10\u201320","journal-title":"Am J Pathol"},{"key":"10054_CR81","doi-asserted-by":"publisher","first-page":"e24671","DOI":"10.1371\/journal.pone.0024671","volume":"6","author":"K-J Chen","year":"2011","unstructured":"Chen K-J, Lin S-Z, Zhou L, Xie H-Y, Zhou W-H, Taki-Eldin A, Zheng S-S (2011) Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS ONE 6:e24671","journal-title":"PLoS ONE"},{"key":"10054_CR82","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/s41419-019-2110-3","volume":"10","author":"S Bidula","year":"2019","unstructured":"Bidula S, Dhuna K, Helliwell R, Stokes L (2019) Positive allosteric modulation of P2X7 promotes apoptotic cell death over lytic cell death responses in macrophages. Cell Death Dis 10:882","journal-title":"Cell Death Dis"},{"key":"10054_CR83","doi-asserted-by":"publisher","first-page":"10830","DOI":"10.1111\/jcmm.15708","volume":"24","author":"C Yang","year":"2020","unstructured":"Yang C, Shi S, Su Y, Tong JS, Li L (2020) P2X7R promotes angiogenesis and tumour-associated macrophage recruitment by regulating the NF-\u03baB signalling pathway in colorectal cancer cells. J Cell Mol Med 24:10830\u201310841","journal-title":"J Cell Mol Med"},{"key":"10054_CR84","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/cancers9060068","volume":"9","author":"AR Dwyer","year":"2017","unstructured":"Dwyer AR, Greenland EL, Pixley FJ (2017) Promotion of tumor invasion by tumor-associated macrophages: the role of CSF-1-activated phosphatidylinositol 3 kinase and Src family kinase motility signaling. Cancers 9:68","journal-title":"Cancers"},{"key":"10054_CR85","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jcmgh.2018.11.002","volume":"7","author":"MA Avila","year":"2019","unstructured":"Avila MA, Berasain C (2019) Targeting CCL2\/CCR2 in tumor-infiltrating macrophages: a tool emerging out of the box against hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol 7:293\u2013294","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10054_CR86","first-page":"11","volume":"2019","author":"E Aric\u00f2","year":"1943","unstructured":"Aric\u00f2 E, Castiello L, Capone I, Gabriele L, Belardelli F (1943) Type I interferons and cancer: an evolving story demanding novel clinical applications. Cancers 2019:11","journal-title":"Cancers"},{"key":"10054_CR87","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.it.2016.04.009","volume":"37","author":"MC Takenaka","year":"2016","unstructured":"Takenaka MC, Robson S, Quintana FJ (2016) Regulation of the T cell response by CD39. Trends Immunol 37:427\u2013439","journal-title":"Trends Immunol"},{"key":"10054_CR88","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/cmi.2017.135","volume":"15","author":"T Yoshimura","year":"2018","unstructured":"Yoshimura T (2018) The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally? Cell Mol Immunol 15:335\u2013345","journal-title":"Cell Mol Immunol"},{"key":"10054_CR89","first-page":"223","volume":"2015","author":"I Bhavsar","year":"2015","unstructured":"Bhavsar I, Miller CS, Al-Sabbagh M (2015) Macrophage inflammatory protein-1 alpha (MIP-1 alpha)\/CCL3: as a biomarker. Gen Methods Biomarker Res App 2015:223","journal-title":"Gen Methods Biomarker Res App"},{"key":"10054_CR90","doi-asserted-by":"publisher","first-page":"8199","DOI":"10.1016\/S0021-9258(18)53082-9","volume":"268","author":"M Murgia","year":"1993","unstructured":"Murgia M, Hanau S, Pizzo P, Rippa M, Di Virgilio F, Oxidized ATP (1993) An irreversible inhibitor of the macrophage purinergic P2Z receptor. J Biological Chem 268:8199\u20138203","journal-title":"J Biological Chem"},{"key":"10054_CR91","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nri3399","volume":"13","author":"E Kolaczkowska","year":"2013","unstructured":"Kolaczkowska E, Kubes P (2013) Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 13:159\u2013175","journal-title":"Nat Rev Immunol"},{"key":"10054_CR92","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.3390\/ijms23063218","volume":"23","author":"S Raftopoulou","year":"2022","unstructured":"Raftopoulou S, Valadez-Cosmes P, Mihalic ZN, Schicho R, Kargl J (2022) Tumor-mediated neutrophil polarization and therapeutic implications. Int J Mol Sci 23:3218","journal-title":"Int J Mol Sci"},{"key":"10054_CR93","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3389\/fimmu.2018.00399","volume":"9","author":"X Wang","year":"2018","unstructured":"Wang X, Chen D (2018) Purinergic regulation of neutrophil function. Front Immunol 9:399","journal-title":"Front Immunol"},{"key":"10054_CR94","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/carcin\/bgs123","volume":"33","author":"ZG Fridlender","year":"2012","unstructured":"Fridlender ZG, Albelda SM (2012) Tumor-associated neutrophils: friend or foe? Carcinogenesis 33:949\u2013955. https:\/\/doi.org\/10.1093\/carcin\/bgs123","journal-title":"Carcinogenesis"},{"key":"10054_CR95","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41389-022-00398-3","volume":"11","author":"H Raskov","year":"2022","unstructured":"Raskov H, Orhan A, Gaggar S, G\u00f6genur I (2022) Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy. Oncogenesis 11:22","journal-title":"Oncogenesis"},{"key":"10054_CR96","doi-asserted-by":"publisher","first-page":"938289","DOI":"10.3389\/fcell.2022.938289","volume":"10","author":"M Yan","year":"2022","unstructured":"Yan M, Zheng M, Niu R, Yang X, Tian S, Fan L, Li Y, Zhang S (2022) Roles of tumor-associated neutrophils in tumor metastasis and its clinical applications. Frontiers Cell Dev Biol 10:938289","journal-title":"Frontiers Cell Dev Biol"},{"key":"10054_CR97","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","volume":"20","author":"S Jaillon","year":"2020","unstructured":"Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A (2020) Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer 20:485\u2013503","journal-title":"Nat Rev Cancer"},{"key":"10054_CR98","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/ijc.28551","volume":"134","author":"J Jablonska","year":"2014","unstructured":"Jablonska J, Wu CF, Andzinski L, Leschner S, Weiss S (2014) CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-\u03b2. Int J Cancer 134:1346\u20131358","journal-title":"Int J Cancer"},{"key":"10054_CR99","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1074\/jbc.M111.315762","volume":"287","author":"Y Wu","year":"2012","unstructured":"Wu Y, Wang S, Farooq SM, Castelvetere MP, Hou Y, Gao J-L, Navarro JV, Oupicky D, Sun F, Li C (2012) A chemokine receptor CXCR2 macromolecular complex regulates neutrophil functions in inflammatory diseases. J Biol Chem 287:5744\u20135755","journal-title":"J Biol Chem"},{"key":"10054_CR100","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41573-019-0032-5","volume":"18","author":"CH Patel","year":"2019","unstructured":"Patel CH, Leone RD, Horton MR, Powell JD (2019) Targeting metabolism to regulate immune responses in autoimmunity and cancer. Nat Rev Drug Discovery 18:669\u2013688","journal-title":"Nat Rev Drug Discovery"},{"key":"10054_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","volume":"30","author":"RM Steinman","year":"2012","unstructured":"Steinman RM (2012) Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30:1\u201322","journal-title":"Annu Rev Immunol"},{"key":"10054_CR102","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","volume":"31","author":"M Merad","year":"2013","unstructured":"Merad M, Sathe P, Helft J, Miller J, Mortha A (2013) The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 31:563\u2013604","journal-title":"Annu Rev Immunol"},{"key":"10054_CR103","doi-asserted-by":"crossref","unstructured":"Cabeza-Cabrerizo, M.; Cardoso, A.; Minutti, C.M.; Pereira da Costa, M.; Reis e Sousa, C. Dendritic cells revisited. Annual review of immunology 2021, 39, 131\u2013166.","DOI":"10.1146\/annurev-immunol-061020-053707"},{"key":"10054_CR104","doi-asserted-by":"publisher","first-page":"101481","DOI":"10.1016\/j.smim.2021.101481","volume":"52","author":"AE Marciscano","year":"2021","unstructured":"Marciscano AE, Anandasabapathy N (2021) The role of dendritic cells in cancer and anti-tumor immunity. In Proceed Sem Immunol 52:101481","journal-title":"In Proceed Sem Immunol"},{"key":"10054_CR105","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.4049\/jimmunol.163.4.1958","volume":"163","author":"C Mutini","year":"1999","unstructured":"Mutini C, Falzoni S, Ferrari D, Chiozzi P, Morelli A, Baricordi OR, Collo G, Ricciardi-Castagnoli P, Di Virgilio F (1999) Mouse dendritic cells express the P2X7 purinergic receptor: characterization and possible participation in antigen presentation. J Immunol 163:1958\u20131965","journal-title":"J Immunol"},{"key":"10054_CR106","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.immuni.2009.09.014","volume":"31","author":"N Martin-Orozco","year":"2009","unstructured":"Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31:787\u2013798","journal-title":"Immunity"},{"key":"10054_CR107","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00262-011-1054-y","volume":"60","author":"M Ankathatti Munegowda","year":"2011","unstructured":"Ankathatti Munegowda M, Deng Y, Mulligan SJ, Xiang J (2011) Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol Immunother 60:1473\u20131484","journal-title":"Cancer Immunol Immunother"},{"key":"10054_CR108","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11302-009-9173-z","volume":"6","author":"E Bulanova","year":"2010","unstructured":"Bulanova E, Bulfone-Paus S (2010) P2 receptor-mediated signaling in mast cell biology. Purinergic Signalling 6:3\u201317","journal-title":"Purinergic Signalling"},{"key":"10054_CR109","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.3389\/fimmu.2019.02074","volume":"10","author":"V Paalme","year":"2019","unstructured":"Paalme V, Rump A, M\u00e4do K, Teras M, Truumees B, Aitai H, Ratas K, Bourge M, Chiang C-S, Ghalali A (2019) Human peripheral blood eosinophils express high levels of the purinergic receptor P2X4. Front Immunol 10:2074","journal-title":"Front Immunol"},{"key":"10054_CR110","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1189\/jlb.0505286","volume":"79","author":"D Ferrari","year":"2006","unstructured":"Ferrari D, la Sala A, Panther E, Norgauer J, Di Virgilio F, Idzko M (2006) Activation of human eosinophils via P2 receptors: novel findings and future perspectives. J Leukoc Biol 79:7\u201315","journal-title":"J Leukoc Biol"},{"key":"10054_CR111","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.alit.2017.02.014","volume":"66","author":"M Nakano","year":"2017","unstructured":"Nakano M, Ito K, Yuno T, Soma N, Aburakawa S, Kasai K, Nakamura T, Takami H (2017) UDP\/P2Y6 receptor signaling regulates IgE-dependent degranulation in human basophils. Allergol Int 66:574\u2013580","journal-title":"Allergol Int"},{"key":"10054_CR112","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3389\/fimmu.2020.02103","volume":"11","author":"G Marone","year":"2020","unstructured":"Marone G, Schroeder JT, Mattei F, Loffredo S, Gambardella AR, Poto R, De Paulis A, Schiavoni G, Varricchi G (2020) Is there a role for basophils in cancer? Front Immunol 11:2103","journal-title":"Front Immunol"},{"key":"10054_CR113","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/JLB.2RU0421-226RR","volume":"112","author":"AVP Alberto","year":"2022","unstructured":"Alberto AVP, da Silva Ferreira NC, Bonavita AGC, Nihei OK, de Farias FP, da Cunha Bisaggio R, de Albuquerque C, Savino W, Coutinho-Silva R, Persechini PM (2022) Physiologic roles of P2 receptors in leukocytes. J Leukocyte Biol 112:983\u20131012","journal-title":"J Leukocyte Biol"},{"key":"10054_CR114","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235\u2013271","journal-title":"Annu Rev Immunol"},{"key":"10054_CR115","doi-asserted-by":"publisher","first-page":"45261","DOI":"10.3389\/fonc.2013.00090","volume":"3","author":"G Schiavoni","year":"2013","unstructured":"Schiavoni G, Gabriele L, Mattei F (2013) The tumor microenvironment: a pitch for multiple players. Front Oncol 3:45261","journal-title":"Front Oncol"},{"key":"10054_CR116","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu Y-X (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14:1014\u20131022","journal-title":"Nat Immunol"},{"key":"10054_CR117","doi-asserted-by":"publisher","first-page":"17462","DOI":"10.18632\/oncotarget.3958","volume":"6","author":"Y Huang","year":"2015","unstructured":"Huang Y, Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Hunborg P, Varvares MA, Hoft DF, Hsueh EC (2015) CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome. Oncotarget 6:17462","journal-title":"Oncotarget"},{"key":"10054_CR118","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMoa051424","volume":"353","author":"F Pag\u00e8s","year":"2005","unstructured":"Pag\u00e8s F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654\u20132666","journal-title":"N Engl J Med"},{"key":"10054_CR119","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.4161\/onci.22009","volume":"1","author":"L Senovilla","year":"2012","unstructured":"Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Saut\u00e8s-Fridman C, Ma Y, Tartour E, Zitvogel L (2012) Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 1:1323\u20131343","journal-title":"Oncoimmunology"},{"key":"10054_CR120","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10585-008-9196-9","volume":"26","author":"TR Mempel","year":"2009","unstructured":"Mempel TR, Bauer CA (2009) Intravital imaging of CD8+ T cell function in cancer. Clin Exp Metas 26:311\u2013327","journal-title":"Clin Exp Metas"},{"key":"10054_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-020-01195-x","volume":"20","author":"L-L Feng","year":"2020","unstructured":"Feng L-L, Cai Y-Q, Zhu M-C, Xing L-J, Wang X (2020) The yin and yang functions of extracellular ATP and adenosine in tumor immunity. Cancer Cell Int 20:1\u201311","journal-title":"Cancer Cell Int"},{"key":"10054_CR122","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.imlet.2018.05.001","volume":"205","author":"D Allard","year":"2019","unstructured":"Allard D, Chrobak P, Allard B, Messaoudi N, Stagg J (2019) Targeting the CD73-adenosine axis in immuno-oncology. Immunol Lett 205:31\u201339","journal-title":"Immunol Lett"},{"key":"10054_CR123","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1158\/2326-6066.CIR-21-0691","volume":"10","author":"KM Wanhainen","year":"2022","unstructured":"Wanhainen KM, Peng C, Zhou MH, Macedo BDG, O\u2019Flanagan S, Yang T, Kelekar A, Burbach BJ, Borges da Silva H, Jameson SC (2022) P2RX7 enhances tumor control by CD8+ T cells in adoptive cell therapy. Cancer Immunol Res 10:871\u2013884","journal-title":"Cancer Immunol Res"},{"key":"10054_CR124","doi-asserted-by":"publisher","first-page":"eaau1022","DOI":"10.1126\/sciimmunol.aau1022","volume":"3","author":"R Stark","year":"2018","unstructured":"Stark R, Wesselink TH, Behr FM, Kragten NA, Arens R, Koch-Nolte F, van Gisbergen KP, van Lier RA (2018) T RM maintenance is regulated by tissue damage via P2RX7. Sci Immunol 3:eaau1022","journal-title":"Sci Immunol"},{"key":"10054_CR125","doi-asserted-by":"publisher","first-page":"13835","DOI":"10.18632\/oncotarget.3453","volume":"6","author":"I Levi","year":"2015","unstructured":"Levi I, Amsalem H, Nissan A, Darash-Yahana M, Peretz T, Mandelboim O, Rachmilewitz J (2015) Characterization of tumor infiltrating natural killer cell subset. Oncotarget 6:13835","journal-title":"Oncotarget"},{"key":"10054_CR126","first-page":"34","volume":"11","author":"B C\u00f3zar","year":"2021","unstructured":"C\u00f3zar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E (2021) Tumor-infiltrating natural killer cells Cancer discovery 11:34\u201344","journal-title":"Tumor-infiltrating natural killer cells Cancer discovery"},{"key":"10054_CR127","doi-asserted-by":"publisher","first-page":"101407","DOI":"10.1016\/j.smim.2020.101407","volume":"48","author":"J Russick","year":"2020","unstructured":"Russick J, Torset C, Hemery E, Cremer I (2020) NK cells in the tumor microenvironment: prognostic and theranostic impact. Recent advances and trends. Proceed Sem Immunol 48:101407","journal-title":"Proceed Sem Immunol"},{"key":"10054_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41388-022-02562-w","volume":"42","author":"Y Yang","year":"2023","unstructured":"Yang Y, Chen L, Zheng B, Zhou S (2023) Metabolic hallmarks of natural killer cells in the tumor microenvironment and implications in cancer immunotherapy. Oncogene 42:1\u201310","journal-title":"Oncogene"},{"key":"10054_CR129","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood-2004-06-2272","volume":"105","author":"JS Palumbo","year":"2005","unstructured":"Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskov\u00e1 M, Degen JL (2005) Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell\u2013mediated elimination of tumor cells. Blood 105:178\u2013185","journal-title":"Blood"},{"key":"10054_CR130","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1007\/s00018-017-2536-7","volume":"74","author":"A Contursi","year":"2017","unstructured":"Contursi A, Sacco A, Grande R, Dovizio M, Patrignani P (2017) Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting. Cell Mol Life Sci 74:3491\u20133507","journal-title":"Cell Mol Life Sci"},{"key":"10054_CR131","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10585-018-9874-1","volume":"35","author":"AJ Gareau","year":"2018","unstructured":"Gareau AJ, Brien C, Gebremeskel S, Liwski RS, Johnston B, Bezuhly M (2018) Ticagrelor inhibits platelet\u2013tumor cell interactions and metastasis in human and murine breast cancer. Clin Exp Metas 35:25\u201335","journal-title":"Clin Exp Metas"},{"key":"10054_CR132","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41577-020-0390-6","volume":"21","author":"D Dersh","year":"2021","unstructured":"Dersh D, Holl\u00fd J, Yewdell JW (2021) A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat Rev Immunol 21:116\u2013128","journal-title":"Nat Rev Immunol"},{"key":"10054_CR133","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cytogfr.2016.07.005","volume":"31","author":"MA Kursunel","year":"2016","unstructured":"Kursunel MA, Esendagli G (2016) The untold story of IFN-\u03b3 in cancer biology. Cytokine Growth Factor Rev 31:73\u201381","journal-title":"Cytokine Growth Factor Rev"},{"key":"10054_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2172-7-22","volume":"7","author":"DH Lee","year":"2006","unstructured":"Lee DH, Park KS, Kong ID, Kim JW, Han BG (2006) Expression of P2 receptors in human B cells and Epstein-Barr virus-transformed lymphoblastoid cell lines. BMC Immunol 7:1\u201311","journal-title":"BMC Immunol"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-024-10054-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-024-10054-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-024-10054-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T08:03:30Z","timestamp":1751443410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-024-10054-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10054"],"URL":"https:\/\/doi.org\/10.1007\/s11302-024-10054-7","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}